 Vivekanand Yadav
Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 13 | 2024 | 28 | 3.680 |
Why?
| | Brain Neoplasms | 12 | 2024 | 45 | 3.030 |
Why?
| | Viral Proteins | 5 | 2017 | 8 | 1.030 |
Why?
| | Animals | 16 | 2024 | 729 | 0.920 |
Why?
| | Mice | 11 | 2024 | 348 | 0.780 |
Why?
| | Endothelial Cells | 2 | 2018 | 25 | 0.770 |
Why?
| | Vaccinia virus | 3 | 2017 | 4 | 0.770 |
Why?
| | Receptors, CXCR4 | 2 | 2016 | 5 | 0.710 |
Why?
| | Glioblastoma | 2 | 2016 | 17 | 0.700 |
Why?
| | Radiation, Ionizing | 1 | 2018 | 1 | 0.640 |
Why?
| | Thymidine Kinase | 1 | 2018 | 2 | 0.640 |
Why?
| | Ganciclovir | 1 | 2018 | 3 | 0.640 |
Why?
| | Simplexvirus | 1 | 2018 | 3 | 0.640 |
Why?
| | Bevacizumab | 1 | 2018 | 3 | 0.640 |
Why?
| | Mutation | 7 | 2023 | 212 | 0.620 |
Why?
| | Complement Pathway, Alternative | 4 | 2017 | 4 | 0.610 |
Why?
| | Humans | 24 | 2024 | 6896 | 0.610 |
Why?
| | Histones | 5 | 2023 | 16 | 0.600 |
Why?
| | Neoplastic Stem Cells | 2 | 2016 | 11 | 0.600 |
Why?
| | Apoptosis | 2 | 2016 | 52 | 0.590 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 13 | 0.570 |
Why?
| | RNA Interference | 1 | 2016 | 16 | 0.570 |
Why?
| | Complement C3b | 4 | 2012 | 4 | 0.530 |
Why?
| | Cell Movement | 1 | 2016 | 71 | 0.530 |
Why?
| | Brain Stem Neoplasms | 3 | 2024 | 3 | 0.480 |
Why?
| | Signal Transduction | 4 | 2023 | 132 | 0.400 |
Why?
| | Complement System Proteins | 2 | 2009 | 5 | 0.390 |
Why?
| | Cell Line, Tumor | 7 | 2024 | 99 | 0.380 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 25 | 0.350 |
Why?
| | Variola virus | 1 | 2008 | 1 | 0.310 |
Why?
| | Brain | 3 | 2023 | 80 | 0.290 |
Why?
| | Oxidative Phosphorylation | 1 | 2024 | 1 | 0.250 |
Why?
| | Cell Differentiation | 1 | 2024 | 59 | 0.240 |
Why?
| | Amino Acid Sequence | 4 | 2017 | 32 | 0.230 |
Why?
| | Cell Proliferation | 3 | 2020 | 58 | 0.220 |
Why?
| | Mice, Inbred C57BL | 3 | 2022 | 92 | 0.220 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2023 | 2 | 0.220 |
Why?
| | Calcium-Binding Proteins | 1 | 2023 | 10 | 0.220 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 13 | 0.220 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 71 | 0.200 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 46 | 0.200 |
Why?
| | Static Electricity | 2 | 2012 | 2 | 0.190 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 4 | 0.190 |
Why?
| | Mice, Transgenic | 2 | 2018 | 35 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 31 | 0.190 |
Why?
| | Everolimus | 1 | 2020 | 2 | 0.190 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 2 | 0.190 |
Why?
| | Dasatinib | 1 | 2020 | 2 | 0.190 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 59 | 0.180 |
Why?
| | Amino Acid Substitution | 2 | 2012 | 12 | 0.180 |
Why?
| | Epigenomics | 1 | 2020 | 27 | 0.180 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 3 | 0.180 |
Why?
| | Spinal Cord Neoplasms | 1 | 2020 | 3 | 0.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 66 | 0.180 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 29 | 0.170 |
Why?
| | Survival Rate | 1 | 2018 | 83 | 0.160 |
Why?
| | Antiviral Agents | 1 | 2018 | 30 | 0.160 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 1 | 0.150 |
Why?
| | Viral Matrix Proteins | 1 | 2017 | 2 | 0.150 |
Why?
| | Viral Tropism | 1 | 2017 | 2 | 0.150 |
Why?
| | Complement Activation | 1 | 2017 | 2 | 0.150 |
Why?
| | Genetic Vectors | 2 | 2015 | 9 | 0.150 |
Why?
| | Female | 4 | 2022 | 3525 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2017 | 2 | 0.150 |
Why?
| | Genetic Therapy | 1 | 2017 | 7 | 0.150 |
Why?
| | Immunotherapy | 1 | 2017 | 16 | 0.140 |
Why?
| | Inflammation | 2 | 2015 | 51 | 0.140 |
Why?
| | Radiation Tolerance | 1 | 2016 | 1 | 0.140 |
Why?
| | Tumor Burden | 1 | 2016 | 3 | 0.140 |
Why?
| | Coculture Techniques | 1 | 2016 | 4 | 0.140 |
Why?
| | Transfection | 1 | 2016 | 22 | 0.140 |
Why?
| | Species Specificity | 2 | 2017 | 10 | 0.140 |
Why?
| | Cattle | 2 | 2017 | 24 | 0.140 |
Why?
| | Chemokine CXCL12 | 1 | 2016 | 1 | 0.140 |
Why?
| | Child | 4 | 2023 | 3364 | 0.140 |
Why?
| | Time Factors | 1 | 2016 | 250 | 0.130 |
Why?
| | Sequence Alignment | 3 | 2017 | 11 | 0.130 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 2 | 0.130 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2015 | 2 | 0.130 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 11 | 0.130 |
Why?
| | Haemophilus Infections | 1 | 2015 | 5 | 0.130 |
Why?
| | Respiratory System | 1 | 2015 | 5 | 0.120 |
Why?
| | Protein Binding | 3 | 2015 | 31 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2015 | 35 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2015 | 54 | 0.120 |
Why?
| | Galectin 1 | 1 | 2014 | 1 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2014 | 13 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 8 | 0.120 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 7 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2014 | 26 | 0.120 |
Why?
| | Dependovirus | 1 | 2014 | 1 | 0.120 |
Why?
| | Antigen-Presenting Cells | 1 | 2014 | 2 | 0.120 |
Why?
| | Central Nervous System | 1 | 2014 | 9 | 0.120 |
Why?
| | Complement C4b | 3 | 2009 | 3 | 0.110 |
Why?
| | Imidazoles | 1 | 2022 | 2 | 0.110 |
Why?
| | Pyridines | 1 | 2022 | 4 | 0.110 |
Why?
| | Pyrimidines | 1 | 2022 | 7 | 0.110 |
Why?
| | Complement Factor I | 1 | 2012 | 1 | 0.110 |
Why?
| | Immune Evasion | 1 | 2012 | 3 | 0.110 |
Why?
| | Herpesvirus 8, Human | 2 | 2010 | 2 | 0.100 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2010 | 19 | 0.100 |
Why?
| | Complement Inactivator Proteins | 1 | 2010 | 1 | 0.090 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2009 | 2 | 0.090 |
Why?
| | Tryptophan | 1 | 2009 | 4 | 0.090 |
Why?
| | Biopsy | 2 | 2023 | 60 | 0.090 |
Why?
| | Herpesvirus 2, Saimiriine | 1 | 2009 | 1 | 0.090 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 10 | 0.080 |
Why?
| | Models, Molecular | 1 | 2008 | 14 | 0.080 |
Why?
| | Surface Plasmon Resonance | 1 | 2008 | 3 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2020 | 7 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2020 | 59 | 0.080 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 55 | 0.070 |
Why?
| | Oligodendroglia | 1 | 2024 | 1 | 0.060 |
Why?
| | Astrocytes | 1 | 2024 | 2 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 15 | 0.060 |
Why?
| | Mitochondria | 1 | 2024 | 11 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 23 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2023 | 1 | 0.060 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 17 | 0.060 |
Why?
| | Male | 2 | 2022 | 3337 | 0.050 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2022 | 7 | 0.050 |
Why?
| | Cell Cycle Checkpoints | 1 | 2022 | 4 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2022 | 5 | 0.050 |
Why?
| | Cell Cycle | 1 | 2022 | 18 | 0.050 |
Why?
| | Glycine | 1 | 2021 | 2 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 68 | 0.050 |
Why?
| | Drug Synergism | 1 | 2020 | 7 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 7 | 0.050 |
Why?
| | Lysine | 1 | 2020 | 3 | 0.050 |
Why?
| | Glycolysis | 1 | 2020 | 4 | 0.050 |
Why?
| | Transplantation, Heterologous | 1 | 2020 | 6 | 0.050 |
Why?
| | Methylation | 1 | 2020 | 11 | 0.050 |
Why?
| | Mice, Nude | 1 | 2020 | 10 | 0.050 |
Why?
| | Mice, SCID | 1 | 2020 | 13 | 0.050 |
Why?
| | Gene Expression | 1 | 2020 | 67 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2020 | 4 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2020 | 5 | 0.040 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 8 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 45 | 0.040 |
Why?
| | Pregnancy | 1 | 2020 | 216 | 0.040 |
Why?
| | Prognosis | 1 | 2020 | 211 | 0.040 |
Why?
| | Fibrinogen | 1 | 2017 | 1 | 0.040 |
Why?
| | Complement C4b-Binding Protein | 1 | 2017 | 1 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2009 | 14 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2009 | 48 | 0.040 |
Why?
| | Dacarbazine | 1 | 2017 | 3 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2016 | 1 | 0.040 |
Why?
| | Transposases | 1 | 2016 | 1 | 0.040 |
Why?
| | Neural Stem Cells | 1 | 2016 | 7 | 0.030 |
Why?
| | Child, Preschool | 1 | 2020 | 1569 | 0.030 |
Why?
| | Haemophilus influenzae | 1 | 2015 | 4 | 0.030 |
Why?
| | Lentivirus | 1 | 2015 | 4 | 0.030 |
Why?
| | Ubiquitination | 1 | 2015 | 7 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2015 | 2 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2015 | 32 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| | Immunologic Surveillance | 1 | 2014 | 1 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2014 | 5 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2014 | 31 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 101 | 0.030 |
Why?
| | Rats | 1 | 2014 | 106 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2014 | 71 | 0.030 |
Why?
| | Disease Progression | 1 | 2014 | 111 | 0.030 |
Why?
| | Models, Biological | 1 | 2014 | 65 | 0.030 |
Why?
| | Adolescent | 1 | 2020 | 2197 | 0.030 |
Why?
| | Algorithms | 1 | 2014 | 105 | 0.030 |
Why?
| | Circular Dichroism | 1 | 2009 | 1 | 0.020 |
Why?
| | Protein Denaturation | 1 | 2009 | 1 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2009 | 1 | 0.020 |
Why?
| | Protein Conformation | 1 | 2009 | 5 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 2009 | 8 | 0.020 |
Why?
| | Fluorescence | 1 | 2009 | 8 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 1 | 0.020 |
Why?
| | Lectins | 1 | 2009 | 2 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 9 | 0.020 |
Why?
| | Ligands | 1 | 2009 | 5 | 0.020 |
Why?
| | Kinetics | 1 | 2009 | 31 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 13 | 0.020 |
Why?
| | Heparin | 1 | 2005 | 6 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 94 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|